AOTMiT: What will the Transparency Council address in September?

TRANSPARENCY COUNCIL MEETING NO. 35/2023 SEPTEMBER 4, 2023

1. Strensiq (asfotasum alfa) CONDITIONAL Indication: under the drug program "Treatment of bone symptoms in the course of pediatric hypophosphatasia (HPP) (ICD-10 E83.3) with asfotasum alfa" Decision problem: preparation of a position paper on the evaluation of the drug

2. Tysabri (natalizumab) solution for injection CONDITIONAL Indication: under drug program B.29. "Treatment of patients with multiple sclerosis (ICD-10: G35)" Decision-making problem: preparing a position paper on the evaluation of the drug

3. phesgo (trastuzumab + pertuzumab) CONDITIONAL Indication: under drug program B.9.FM. "Treatment of patients with breast cancer (ICD-10: C50)". Decision-making problem: preparation of a position on the evaluation of the drug

4. Nilemdo (bempedoic acid) Indication: atherosclerosis Decision-making problem: preparation of a position on the appropriateness of granting reimbursement approval for a medicinal product

5. "Support of infertility treatment by in vitro fertilization - in vitro for residents of the Oświęcim district in 2024-2026". Decision-making problem: preparation of an opinion on the draft health policy program of local government units

TRANSPA...